Compare FBP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | IRON |
|---|---|---|
| Founded | 1948 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | FBP | IRON |
|---|---|---|
| Price | $21.38 | $76.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $23.67 | ★ $108.85 |
| AVG Volume (30 Days) | ★ 1.2M | 651.6K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 13.12 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $902,789,000.00 | N/A |
| Revenue This Year | $16.04 | N/A |
| Revenue Next Year | $4.02 | N/A |
| P/E Ratio | $10.35 | ★ N/A |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $16.40 | $30.82 |
| 52 Week High | $22.61 | $99.50 |
| Indicator | FBP | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 58.39 | 32.60 |
| Support Level | $20.47 | $76.24 |
| Resistance Level | $21.57 | $80.32 |
| Average True Range (ATR) | 0.39 | 3.95 |
| MACD | -0.04 | -0.91 |
| Stochastic Oscillator | 57.36 | 24.64 |
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.